What is the recommended treatment for influenza, including antiviral options, dosing, and considerations for high‑risk patients?

Influenza Treatment

Start antiviral treatment immediately with oseltamivir for all hospitalized patients, those with severe/progressive illness, high-risk patients (including pregnant women, adults ≥65 years, children <2 years, immunocompromised, and those with chronic medical conditions), regardless of illness duration or time since symptom onset 1.

Antiviral Selection and Dosing

First-Line Treatment

• Oseltamivir (oral) is the primary recommended neuraminidase inhibitor for most patients, particularly those with severe influenza 1, 2
• Standard 5-day course for uncomplicated influenza in otherwise healthy ambulatory patients 1
• Do not use higher than FDA-approved doses routinely for seasonal influenza 1
• Oseltamivir demonstrates reduced viral shedding, faster symptom resolution, and lower complication rates, though gastrointestinal side effects are common 3

Alternative Antivirals

• Inhaled zanamivir or intravenous peramivir are acceptable alternatives as single-agent therapy 1
• Baloxavir is conditionally recommended for high-risk non-severe cases within 48 hours of symptom onset, showing superior viral load reduction 2, 4
• Zanamivir is more effective against influenza B and works against oseltamivir-resistant influenza A, but the inhaled formulation is unsuitable for severe illness or airway disease 3

Critical Treatment Principles

• Never combine neuraminidase inhibitors 1
• Start treatment as soon as possible—the 48-hour window is a guideline, not an absolute cutoff, especially for hospitalized or high-risk patients 1
• Treatment within 48 hours primarily shortens illness duration by approximately 1 day in healthy outpatients 5

High-Risk Populations Requiring Treatment

The following groups warrant immediate antiviral treatment regardless of illness duration 1:

• Hospitalized patients of any age
• Severe or progressive illness at any stage
• Pregnant women and postpartum (within 2 weeks)
• Adults ≥65 years
• Children <2 years
• Immunocompromised patients
• Chronic medical conditions (cardiac, pulmonary, metabolic, renal, hepatic, neurologic)

Special Considerations

Extended Treatment Duration

Consider longer than 5-day treatment for 1:

• Immunocompromised patients with documented or suspected conditions
• Hospitalized patients with severe lower respiratory tract disease (pneumonia or ARDS)
• Patients with persistent viral replication (influenza replication is often protracted in these populations)

Bacterial Coinfection Management

Empirically treat bacterial coinfection in addition to antivirals when 1:

• Patients present initially with severe disease (extensive pneumonia, respiratory failure, hypotension, fever)
• Patients deteriorate after initial improvement
• Consider investigation if no improvement after 3-5 days of antiviral treatment

Strong recommendation against antibiotics for non-severe influenza without evidence of bacterial infection 2, 4

Adjunctive Therapies

Do not use the following in severe influenza 2, 4:

• Corticosteroids (conditional recommendation against)
• Macrolides (unless bacterial coinfection documented)
• mTOR inhibitors
• NSAIDs
• Passive immune therapy/convalescent plasma

Antiviral Resistance Testing

Consider resistance testing for 1:

• Laboratory-confirmed influenza developing during or immediately after neuraminidase inhibitor prophylaxis
• Immunocompromised patients with persistent viral replication (>7-10 days) who remain ill during/after treatment
• Patients receiving subtherapeutic dosing inadvertently
• Severe influenza without improvement despite treatment and evidence of persistent replication

Prophylaxis Recommendations

Conditionally recommend prophylaxis with baloxavir, laninamivir, oseltamivir, or zanamivir for 2, 4:

• Anyone exposed to zoonotic influenza (novel influenza A)
• Those exposed to seasonal influenza who are at extremely high risk of hospitalization
• Do not use prophylaxis as replacement for vaccination 4

Diagnostic Testing Strategy

• NAAT (nucleic acid amplification test) for suspected severe influenza 2, 4
• Digital immunoassay (DIA) or NAAT for non-severe influenza 2, 4
• Do not use viral culture for initial diagnosis—results are not timely for clinical management 1
• Do not use serologic testing for acute diagnosis 1

Common Pitfalls

• Waiting for test results: Start treatment empirically in high-risk or hospitalized patients before confirmation 1
• Dismissing treatment after 48 hours: Hospitalized and high-risk patients benefit from treatment regardless of symptom duration 1
• Using combination neuraminidase inhibitors: No evidence of benefit and not recommended 1
• Routine antibiotic use: Strong recommendation against unless bacterial coinfection is documented or highly suspected 2
• Healthy, low-risk outpatients: Clinical benefit is modest with high risk of side effects—treatment is optional in this population 5